Activation of 4-1BB signalling in exhausted T cells has been shown to promote their proliferation and differentiation [45, 46], making 4-1BB an attractive target for developing immune based therapeutics, especially in tumours that display a relatively immunosuppressed tumour microenvironment. Here, TNFRSF9 is linked to neoplasm.